Skip to Main Content

An experimental migraine pill from Biohaven Pharmaceuticals (BHVN) hit its primary endpoints of beating placebo in pain relief and prevention of symptoms including light sensitivity and nausea in two Phase 3 clinical trials, the company announced Monday.

With the study results, Biohaven said it will submit a marketing application for the migraine drug, called rimegepant, with the Food and Drug Administration next year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.